BioCentury reported a clinical setback for Insmed’s Brinsupri that triggered a sharp market reaction and a reduction in the company’s market capitalization. The report details clinical data or safety signals that caused investor reassessment of the program’s commercial potential. The update arrived alongside other corporate clinical news and highlights how single‑product or near‑term readout risks can materially affect small‑cap biotech valuations. Insmed is undertaking data reviews and investor communications to address the shortfall.